Sorin Group S.p.A. Launches REPLY™ 200 Family of Pacemakers With Sleep Apnea Monitoring for Better Management of Cardiovascular Co-Morbidities1

Published: Jun 18, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MILAN--(BUSINESS WIRE)--Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today CE mark approval and the European commercial launch of the REPLY ™ 200 family of pacemakers featuring Sleep Apnea Monitoring (SAM)2. Sleep apnea is highly prevalent3 and vastly undiagnosed4 in pacemaker patients. It increases the mortality risk and the risk of common cardiovascular co-morbidities such as hypertension, atrial fibrillation (AF) and heart failure (HF). Moreover, sleep apnea complicates the management of common cardiovascular co-morbidities5,6.

Help employers find you! Check out all the jobs and post your resume.

Back to news